Loading...
•
Sep 30, 2020
Ionis Q3 2020 Earnings Report
Ionis reported third quarter 2020 financial results, highlighting the Akcea acquisition and pipeline advancements.
Key Takeaways
Ionis Pharmaceuticals reported a net loss of $31 million on a GAAP basis but achieved a net income of $5 million on a non-GAAP basis for Q3 2020. The company saw quarter-over-quarter revenue growth, driven by SPINRAZA royalties, increased product sales from TEGSEDI and WAYLIVRA, and advancements in partnered R&D programs. Ionis maintained a strong balance sheet with $2.3 billion in cash.
Acquired Akcea Therapeutics to enhance commercial strategy and pipeline value.
Advanced inhaled delivery with IONIS-ENAC-2.5Rx for pulmonary diseases.
Initiated mid-stage studies for vupanorsen in cardiovascular disease and ION541 for ALS.
Progressed five Phase 3 studies, with a sixth expected to begin by the end of the year.
Revenue by Segment
Forward Guidance
Ionis is maintaining its 2020 financial guidance, expecting significant revenue and earnings growth in the fourth quarter, driven by multiple revenue sources, including a $75 million payment from Pfizer for advancing vupanorsen.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...